Allos Therapeutics, Inc. (NASDAQ:ALTH)
| CAPS Rating |
|
|---|---|
| Open | $1.75 |
| Previous Close | $1.76 |
| Daily Range | $1.68 - $1.75 |
| 52-Week Range | $1.25 - $3.42 |
| Market Cap | $179.65M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 225,334 |
| Average Daily Volume | 0 |
ALTH
VS S&P 500 (SPY)
How do you think ALTH will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
ALTH Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
ALTH News and Commentary
- ALTH Seeks Review of Folotyn Verdict - Analyst Blog – NASDAQ
- European Setback for Allos - Analyst Blog – NASDAQ
- Allos Therapeutics Cut to Neutral - Analyst Blog – NASDAQ
- AMAG Q4 Sales Set to Disappoint - Analyst Blog – NASDAQ
- AMAG's Feraheme Gets Canada Nod - Analyst Blog – NASDAQ
- Allos Continues to Outperform - Analyst Blog – NASDAQ
- AMAG Hires Financial Advisor - Analyst Blog – NASDAQ
- Stocks Rally on European Debt Summit Optimism; December Crude Surges Over 2% – NASDAQ
- Mid-Day Update: Stocks Surge, Indexes Top 1% on Europe Debt Optimism, Earnings – NASDAQ
- Why Did My Stock Just Die? – The Motley Fool
- These Underdogs Are No Dogs – The Motley Fool
- Options Traders Think These Beaten Up Stocks Are Ready for a Rebound – NASDAQ
- Investing 101: Options Traders Think These Beaten Up Stocks Are Ready for a Rebound – The Motley Fool
- Buybacks That Are Better Than Dividends – The Motley Fool
- Whoa! What Just Happened to My Stock? – The Motley Fool
- What's a Cancer Drug Worth? – Minyanville
- 2nd UPDATE: AMAG Pharma Gets Offer From Fund Opposing Allos Deal – SmartMoney
- Hedge Fund Offers $378 Million for Amag in Unsolicited Bid – Minyanville
- 9 Small Biotechs Near 52-Week Lows – The Motley Fool
- AMAG-Allos, a Match Made in Necessity – The Motley Fool
RSS Headlines
Fool UK
